

# Ronny Drapkin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5704001/ronny-drapkin-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

18,082  
citations

62  
h-index

134  
g-index

170  
ext. papers

20,726  
ext. citations

12.4  
avg, IF

6.18  
L-index

#	Paper	IF	Citations
154	The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.. <i>Science Signaling</i> , <b>2022</b> , 15, eabm2496	8.8	0
153	Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. <i>Cancer Research</i> , <b>2021</b> , 81, 806-810	10.1	5
152	Predicting master transcription factors from pan-cancer expression data. <i>Science Advances</i> , <b>2021</b> , 7, eabf6433	11.3	2
151	The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 1413-1424	12.5	2
150	Flower lose, a cell fitness marker, predicts COVID-19 prognosis. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13714	11	0
149	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> ,	4	2
148	Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 1168-1181	6.6	3
147	Tumor innervation: peripheral nerves take control of the tumor microenvironment. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	11
146	Cell Fitness: More Than Push-Ups. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
145	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. <i>Nature Cancer</i> , <b>2021</b> , 2, 189-200	15.4	6
144	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 5706-5719	10.1	9
143	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. <i>Nature Communications</i> , <b>2020</b> , 11, 2717	17.4	12
142	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , <b>2020</b> , 16, e1008808	6	15
141	miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. <i>Nature Communications</i> , <b>2020</b> , 11, 3231	17.4	11
140	The tubal epigenome - An emerging target for ovarian cancer. <i>Pharmacology &amp; Therapeutics</i> , <b>2020</b> , 210, 107524	13.9	6
139	Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	7
138	Tumor Innervation: Cancer Has Some Nerve. <i>Trends in Cancer</i> , <b>2020</b> , 6, 1059-1067	12.5	14

137	Combined MEK and BCL-2/X Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 642-655	6.1	26
136	Testing ovarian cancer cell lines to train dogs to detect ovarian cancer from blood plasma: A pilot study. <i>Journal of Veterinary Behavior: Clinical Applications and Research</i> , <b>2019</b> , 32, 42-48	1.9	11
135	Innervation of cervical carcinoma is mediated by cancer-derived exosomes. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 228-235	4.9	24
134	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , <b>2019</b> , 125, 1963-1972	6.4	22
133	Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. <i>Cancer Research</i> , <b>2019</b> , 79, 5536-5549	10.1	9
132	CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. <i>Cancers</i> , <b>2019</b> , 11,	6.6	9
131	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 760-772	10.1	25
130	Precious GEMMs: emergence of faithful models for ovarian cancer research. <i>Journal of Pathology</i> , <b>2018</b> , 245, 129-131	9.4	19
129	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. <i>Nature Communications</i> , <b>2018</b> , 9, 631	17.4	55
128	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 585-591	4.9	38
127	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. <i>Cell Reports</i> , <b>2018</b> , 25, 2617-2633	10.6	49
126	Expression of the POTE gene family in human ovarian cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 17136	4.9	13
125	CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 14725	4.9	19
124	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. <i>Journal of Pathology</i> , <b>2018</b> , 246, 459-469	9.4	15
123	Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. <i>Oncogenesis</i> , <b>2017</b> , 6, e295	6.6	38
122	Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , <b>2017</b> , 18, 2343-2358	10.6	33
121	Pathogenesis and heterogeneity of ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2017</b> , 29, 26-34	2.4	135
120	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , <b>2017</b> , 8, 1093	17.4	325

119	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. <i>Nature Communications</i> , <b>2017</b> , 8, 365	17.4	33
118	PRKCI promotes immune suppression in ovarian cancer. <i>Genes and Development</i> , <b>2017</b> , 31, 1109-1121	12.6	43
117	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1263-1273	12.9	67
116	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1862-1874	12.9	78
115	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. <i>JCI Insight</i> , <b>2017</b> , 2, e89760	9.9	49
114	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , <b>2016</b> , 29, 1254-61	9.8	54
113	SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. <i>Oncogenesis</i> , <b>2016</b> , 5, e264	6.6	15
112	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 329ra34	17.5	25
111	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 713-20	3.2	6
110	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. <i>Cell Reports</i> , <b>2016</b> , 14, 429-439	10.6	91
109	Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. <i>OncImmunology</i> , <b>2016</b> , 5, e1090075	7.2	34
108	It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. <i>Cancer Research</i> , <b>2016</b> , 76, 10-7	10.1	82
107	YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. <i>Oncogene</i> , <b>2016</b> , 35, 2247-65	9.2	46
106	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	28
105	Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	28
104	Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. <i>Cell</i> , <b>2015</b> , 160, 977-989	56.2	237
103	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. <i>Oncogene</i> , <b>2015</b> , 34, 373-83	9.2	31
102	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 8234	17.4	40

101	Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 104-11	4.9	34
100	PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. <i>Molecular Cell</i> , <b>2015</b> , 60, 571-83	17.6	126
99	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 668-79	31.3	581
98	Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 97-103	4.9	52
97	Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer. <i>FASEB Journal</i> , <b>2015</b> , 29, 576-88	0.9	38
96	GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 1411-9	6.7	98
95	GATA3 expression in gestational trophoblastic tissues and tumours. <i>Histopathology</i> , <b>2015</b> , 67, 636-44	7.3	28
94	Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. <i>Oncotarget</i> , <b>2015</b> , 6, 38983-98	3.3	31
93	Tumor-Targeted Synergistic Blockade of MAPK and PI3K From a Layer-by-Layer Nanoparticle. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4410-9	12.9	40
92	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , <b>2015</b> , 521, 489-94	50.4	890
91	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 3595-607	5.6	32
90	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4960-9	12.9	44
89	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , <b>2015</b> , 13, 2395-2402	10.6	75
88	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 232-7	11.5	112
87	Elafin: a double agent in breast and ovarian cancer. <i>Oncoscience</i> , <b>2015</b> , 2, 793-4	0.8	0
86	Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 1383-93	4	22
85	The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. <i>Reproductive Biology and Endocrinology</i> , <b>2014</b> , 12, 60	5	34
84	Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. <i>Cancer Research</i> , <b>2014</b> , 74, 1141-52	10.1	102

83	Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Müllerian antigens. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 316-21	4.9	23
82	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 328-33	4.9	14
81	FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. <i>Oncogene</i> , <b>2014</b> , 33, 4424-32	9.2	21
80	In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 1102-7	11.5	35
79	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 2611-25	15.9	84
78	CD151- $\beta$ 1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. <i>Oncotarget</i> , <b>2014</b> , 5, 12203-17	3.3	36
77	Cancers Arising in the Ovary <b>2014</b> , 1592-1613.e6		1
76	Coming into focus: the nonovarian origins of ovarian cancer. <i>Annals of Oncology</i> , <b>2013</b> , 24 Suppl 8, viii28-viii35		64
75	There is a need for routine peritoneal cytology at RRSO. <i>Gynecologic Oncology</i> , <b>2013</b> , 128, 149-150	4.9	1
74	Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. <i>Human Pathology</i> , <b>2013</b> , 44, 734-42	3.7	29
73	Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. <i>Cancer Cell</i> , <b>2013</b> , 24, 751-65	24.3	366
72	Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. <i>Molecular Oncology</i> , <b>2013</b> , 7, 419-27	7.9	23
71	HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 6026-43	6.3	46
70	HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. <i>International Journal of Molecular Sciences</i> , <b>2013</b> , 14, 22655-77	6.3	20
69	Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 89-97	6.7	23
68	Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 217	5.3	30
67	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 517-25	15.9	371
66	Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. <i>Gynecologic Oncology</i> , <b>2012</b> , 124, 270-5	4.9	67

65	Primary culture and immortalization of human fallopian tube secretory epithelial cells. <i>Nature Protocols</i> , <b>2012</b> , 7, 1755-64	18.8	97
64	Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5806-15	12.9	118
63	Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 147ra112	17.5	135
62	Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e30269	3.7	84
61	The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. <i>PLoS ONE</i> , <b>2012</b> , 7, e46486	3.7	15
60	Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. <i>Science</i> , <b>2011</b> , 334, 1129-33	33.3	417
59	Ex vivo culture of primary human fallopian tube epithelial cells. <i>Journal of Visualized Experiments</i> , <b>2011</b> ,	1.6	16
58	High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. <i>PLoS ONE</i> , <b>2011</b> , 6, e24433	3.7	35
57	A comprehensive analysis of PAX8 expression in human epithelial tumors. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 816-26	6.7	334
56	Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 1531-9	6.7	23
55	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 719-25	31.3	893
54	Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. <i>Gynecologic Oncology</i> , <b>2011</b> , 123, 5-12	4.9	63
53	Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 7547-52	11.5	209
52	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 12372-7	11.5	321
51	The new face of ovarian cancer modeling: better prospects for detection and treatment. <i>F1000 Medicine Reports</i> , <b>2011</b> , 3, 22		14
50	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. <i>Nature Structural and Molecular Biology</i> , <b>2010</b> , 17, 688-95	17.6	707
49	Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. <i>Oncogene</i> , <b>2010</b> , 29, 1103-13	9.2	156
48	Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. <i>Neoplasia</i> , <b>2010</b> , 12, 161-72	6.4	46

47	PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. <i>American Journal of Surgical Pathology</i> , <b>2010</b> , 34, 627-35	6.7	177
46	An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. <i>Cancer Cell</i> , <b>2010</b> , 17, 298-310	24.3	183
45	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. <i>Cancer Cell</i> , <b>2010</b> , 17, 412	24.3	3
44	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. <i>Histopathology</i> , <b>2009</b> , 55, 619	7.3	24
43	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. <i>Histopathology</i> , <b>2008</b> , 53, 127-38	7.3	81
42	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. <i>Gynecologic Oncology</i> , <b>2008</b> , 109, 168-73	4.9	218
41	A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. <i>Gastroenterology</i> , <b>2008</b> , 134, 511-22	13.3	124
40	Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube?. <i>Fertility and Sterility</i> , <b>2008</b> , 90, 2008.e5-8	4.8	9
39	Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2647-55	12.9	26
38	Urokinase-type plasminogen activator receptor: a beacon of malignancy?. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5643-5	12.9	6
37	Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6478-86	12.9	67
36	A novel breast cancer-associated BRIP1 (FANCI/BACH1) germ-line mutation impairs protein stability and function. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4672-80	12.9	46
35	New insights into the pathogenesis of serous ovarian cancer and its clinical impact. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5284-93	2.2	302
34	Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. <i>International Journal of Gynecological Pathology</i> , <b>2008</b> , 27, 390-7	3.2	34
33	Serous carcinogenesis in the fallopian tube: a descriptive classification. <i>International Journal of Gynecological Pathology</i> , <b>2008</b> , 27, 1-9	3.2	230
32	A candidate precursor to serous carcinoma that originates in the distal fallopian tube. <i>Journal of Pathology</i> , <b>2007</b> , 211, 26-35	9.4	645
31	A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26B5). <i>Journal of Pathology</i> , <b>2007</b> , 213, 116-116	9.4	4
30	A recurrent mutation in PALB2 in Finnish cancer families. <i>Nature</i> , <b>2007</b> , 446, 316-9	50.4	349



29	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. <i>Clinical Medicine and Research</i> , <b>2007</b> , 5, 35-44	1.4	250
28	Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 737-43	6.7	85
27	The distal fallopian tube: a new model for pelvic serous carcinogenesis. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2007</b> , 19, 3-9	2.4	361
26	Further evidence for BRCA1 communication with the inactive X chromosome. <i>Cell</i> , <b>2007</b> , 128, 991-1002	56.2	67
25	Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. <i>Cancer Research</i> , <b>2005</b> , 65, 2162-9	10.1	399
24	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. <i>Genes and Development</i> , <b>2005</b> , 19, 489-501	12.6	987
23	Association of BRCA1 with the inactive X chromosome and XIST RNA. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2004</b> , 359, 123-8	5.8	30
22	The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 2357-62	11.5	190
21	Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. <i>Human Pathology</i> , <b>2004</b> , 35, 1014-21	3.7	61
20	Unilateral transverse arm defect with subterminal digital nubbins. <i>Pediatric and Developmental Pathology</i> , <b>2003</b> , 6, 348-54	2.2	8
19	The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. <i>Cell</i> , <b>2003</b> , 113, 357-67	56.2	604
18	BRCA1 supports XIST RNA concentration on the inactive X chromosome. <i>Cell</i> , <b>2002</b> , 111, 393-405	56.2	255
17	BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. <i>Cell</i> , <b>2001</b> , 105, 149-60	56.2	520
16	The p400 complex is an essential E1A transformation target. <i>Cell</i> , <b>2001</b> , 106, 297-307	56.2	257
15	Immunoaffinity purification of the human multisubunit transcription factor IIH. <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273, 7134-40	5.4	24
14	RNA polymerase II stalled at a thymine dimer: footprint and effect on excision repair. <i>Nucleic Acids Research</i> , <b>1997</b> , 25, 787-93	20.1	159
13	Purification of human RNA polymerase II and general transcription factors. <i>Methods in Enzymology</i> , <b>1996</b> , 274, 72-100	1.7	75
12	Human cyclin-dependent kinase-activating kinase exists in three distinct complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 6488-93	11.5	147

11	A human RNA polymerase II complex associated with SRB and DNA-repair proteins. <i>Nature</i> , <b>1996</b> , 381, 86-9	50.4	312
10	Cdk-activating kinase complex is a component of human transcription factor TFIID. <i>Nature</i> , <b>1995</b> , 374, 283-7	50.4	381
9	The 62- and 80-kDa subunits of transcription factor IIF mediate the interaction with Epstein-Barr virus nuclear protein 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1995</b> , 92, 3259-63	11.5	103
8	The multifunctional TFIID complex and transcriptional control. <i>Trends in Biochemical Sciences</i> , <b>1994</b> , 19, 504-8	10.3	80
7	Dual role of TFIID in DNA excision repair and in transcription by RNA polymerase II. <i>Nature</i> , <b>1994</b> , 368, 769-72	50.4	635
6	Where transcription meets repair. <i>Cell</i> , <b>1994</b> , 77, 9-12	56.2	146
5	Regulation of RNA polymerase II transcription. <i>Current Opinion in Cell Biology</i> , <b>1993</b> , 5, 469-76	9	89
4	Predicting master transcription factors from pan-cancer expression data		4
3	Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance		4
2	PAX8 orchestrates an angiogenic program through interaction with SOX17		2
1	Fallopian tube precursor lesions of serous ovarian carcinoma require L1CAM for dissemination and metastasis		3